Nanjing Leads Biolabs Cash Flow Statement

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023
Net Income	-211.42	-301.22	-362.25
Depreciation & Amortization	21.21	26.04	23.91
Loss (Gain) From Sale of Assets	0	-	-
Loss (Gain) From Sale of Investments	-0.54	-1.72	-6.24
Stock-Based Compensation	9.85	41.94	17.84
Other Operating Activities	27.49	45.81	115.96
Change in Inventory	-58.02	-	2.04
Change in Accounts Payable	5.24	25.05	-1.55
Change in Unearned Revenue	93.99	84.22	-
Change in Other Net Operating Assets	-42.22	-38.94	17.61
Operating Cash Flow	-154.43	-118.82	-192.69
Capital Expenditures	-8.23	-2.98	-11.73
Sale of Property, Plant & Equipment	0	-	-
Sale (Purchase) of Intangibles	-2.19	-	-
Investment in Securities	-154.71	-64.33	147.22
Investing Cash Flow	-165.13	-67.3	135.49
Long-Term Debt Issued	341	274.98	61
Long-Term Debt Repaid	-341.63	-86.34	-4.64
Net Debt Issued (Repaid)	-0.63	188.64	56.37
Issuance of Common Stock	1,350	130.51	-
Repurchase of Common Stock	-72.67	-	-
Other Financing Activities	-86.35	-10.12	-6.87
Financing Cash Flow	1,190	309.02	49.49
Foreign Exchange Rate Adjustments	-22.08	2.12	2.7
Net Cash Flow	848.61	125.02	-5
Free Cash Flow	-162.65	-121.79	-204.41
Free Cash Flow Margin	-91.76%	-	-2305.84%
Free Cash Flow Per Share	-0.93	-0.81	-1.41
Cash Interest Paid	6.55	5.19	6.87
Levered Free Cash Flow	-92.39	-1,339	-
Unlevered Free Cash Flow	-87.9	-1,336	-
Change in Working Capital	-1.01	70.33	18.09

Source: S&P Global Market Intelligence. Standard template. Financial Sources.